Nachrichten zur Biogen Inc. Aktie

Biogens Phase II/III SMA Study for Higher Spinraza Dose Meets Goals

BIIBs pivotal mid to late-stage study evaluating a higher dosing regimen for Spinraza to treat SMA in infants meets the…

Biogen Inc.s (BIIB) Morgan Stanleys 22nd Annual Global Healthcare Conference Transcript

…

Long Term Investor News: Biogen, Seritage Growth, Arbor Realty, and Five Below Investors are Encouraged to Contact Johnson Fistel, LLP for Their Options

SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is conducting a thorough investigation into possible…

Eli Lilly Alzheimer’s drug set to face same fate as Biogen’s in U.K.: report

…

Biogen: Q2 Earnings, Share Price May Have Bottomed Out As CEO Makes Mark

…

Biogen: Kursziel gekappt

New York (www.aktiencheck.de) - Rating-Update: Die Analysten von Mizuho Securities USA stufen die Aktie von Biogen Inc. (ISIN: US09062X1037, WKN: 789617,…

Biogen: Kursziel reduziert

Vancouver (www.aktiencheck.de) - Rating-Update: Die Analysten von Canaccord Genuity bestätigen das "buy"-Votum für die Aktie von Biogen Inc. (ISIN: US09062X1037, WKN:…

Biogen: Kursziel gesenkt

Charlotte, NC (www.aktiencheck.de) - Rating-Update: Die Analysten von Truist bestätigen das "buy"-Votum für die Aktie von Biogen Inc. (ISIN: US09062X1037, WKN:…

Biogen Aktie: Positive Aussichten trotz Herausforderungen

Die Biotechnologiefirma verzeichnete im zweiten Quartal starke Finanzergebnisse, die die Erwartungen der Analysten übertrafen. Mit einem Umsatz von 2,5 Milliarden…

Biogen: Kursziel gekürzt

London (www.aktiencheck.de) - Rating-Update: Die Analysten von Barclays stufen die Aktie von Biogen Inc. (ISIN: US09062X1037, WKN: 789617, Ticker-Symbol: IDP, NASDAQ-Symbol:…

Biogen: Kurszielerhöhung

Toronto (www.aktiencheck.de) - Rating-Update: Die Analysten vom Investmenthaus RBC Capital Markets stufen die Aktie von Biogen Inc. (ISIN: US09062X1037, WKN: 789617,…

Biogen: Endlich auf dem Weg zur Kostensenkung? Aktienanalyse

Toronto (www.aktiencheck.de) - Biogen-Aktienanalyse von der Scotiabank: Die Analysten der Scotiabank belassen die Aktie von Biogen Inc. (ISIN: US09062X1037, WKN: 789617,…

Biogen (BIIB) Q2 2024 Earnings Call Transcript

BIIB earnings call for the period ending June 30, 2024.…

Biogen Inc. 2024 Q2 - Results - Earnings Call Presentation

…

Biogen beats expectations, hikes outlook as Alzheimers drug Leqembi and other new products gain traction

Uptake of Biogens breakthrough Alzheimers drug, Leqembi, appears to be picking up, with roughly $40 million in sales for the…

Biogen lifts 2024 profit forecast on cost cuts, drug launches By Reuters

Biogen lifts 2024 profit forecast on cost cuts, drug launches…

Leqembi revenue more than doubled – totaled JPY 6.3 billion in the second quarter 2024

Stockholm, Sweden, August 1, 2024 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global…

Biogen (BIIB) Q2 Earnings & Sales Beat, 2024 Guidance Raised

Biogen (BIIB) beats second-quarter estimates for both earnings and sales. It raises EPS guidance and revenue growth expectations for 2024.…

Biotech Stock Roundup: BMY, GSK, BIIBs Q2 Results, VTVT Down on Setback

Bristol Myers (BMY) and Biogen (BIIB) are in the spotlight following earnings results and regulatory updates, respectively.…

Patients on Alzheimers drug Leqembi see benefits over three years, Eisai study says

The study results on Leqembi, which Eisai shares with Biogen, also found that Alzheimers patients who take the therapy get…

Biogen, Beckman Coulter und Fujirebio arbeiten gemeinsam an blutbasierten Biomarkern und Tests für Tau-Pathologie bei Alzheimer-Krankheit

CAMBRIDGE, Massachusets. & BREA, Kalifornien & TOKIO--(BUSINESS WIRE)--Biogen Inc. (Nasdaq: BIIB), Beckman Coulter, Inc. und Fujirebio gaben eine Zusammenarbeit bekannt,…

Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease

CAMBRIDGE, Mass. and BREA, Calif. and TOKYO, July 30, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB), Beckman…

Biogen: Kurszielsenkung

Milwaukee (www.aktiencheck.de) - Rating-Update: Die Analysten von Robert W. Baird stufen die Aktie von Biogen Inc. (ISIN: US09062X1037, WKN: 789617, Ticker-Symbol:…

Biogen Aktie: Alzheimer-Medikament erleidet Rückschlag

Der Pharmakonzern Biogen und sein japanischer Partner Eisai haben einen Rückschlag bei der Zulassung ihres Alzheimer-Medikaments Leqembi in Europa erlitten.…

Eisai slumps 13% as EU regulators reject Alzheimer’s treatment developed with Biogen By Investing.com

Eisai slumps 13% as EU regulators reject Alzheimer’s treatment developed with Biogen…

Europe Just Turned Down Biogens Alzheimers Drug. Is the Stock One to Avoid, or a Bad News Buy?

Biogen stock has slipped 18% so far this year.…

Europe Just Turned Down Biogens Alzheimers Drug. Is the Stock One to Avoid, or a Bad News Buy? @themotleyfool #stocks $BIIB $ESALY

Biogen stock has slipped 18% so far this year.…

Eisai Shares Sink on Surprise EU Rejection of Alzheimer’s Drug

Eisai shares sink more than 12%, the most in three years, after European drug regulators rejected an Alzheimer’s therapy jointly…

What Awaits Biogen (BIIB) in Q2 Earnings Post Leqembi Setback?

Biogens (BIIB) sales in the second quarter are likely to have been hurt by lower sales of its multiple sclerosis…

Biogen: Aktie immer noch deutlich unterbewertet - Aktienanalyse

Toronto (www.aktiencheck.de) - Biogen-Aktienanalyse von RBC Capital Markets: Die Analysten von RBC Capital Markets reduzieren in einer aktuellen Aktienanalyse ihr Kursziel…

Biogen: Böse Überraschung - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Biogen-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Biogen Inc. (ISIN: US09062X1037,…

Biogen-Aktie bricht ein, BioArctic crasht: Massiver Rückschlag

Böse Überraschung für Biogen, Eisai und BioArctic. Der Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittel-Agentur (EMA) hat eine Empfehlung für…

Biogen-Aktie bricht ein, BioArctic crasht: Massiver Rückschlag

Böse Überraschung für Biogen, Eisai und BioArctic. Der Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittel-Agentur (EMA) hat eine Empfehlung für…

ROUNDUP: EU-Behörde lehnt Empfehlung von Alzheimer-Medikament ab

AMSTERDAM (dpa-AFX) - Es wäre die erste zugelassene ursächliche Alzheimer-Therapie in der EU gewesen: Überraschend hat…

European drug regulator rejects Alzheimers treatment Leqembi from Biogen, Eisai

The committee said Leqembis effect on delaying cognitive decline does not outweigh "the risk of serious side effects associated with…

BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)

LOS ANGELES, July 17, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the…

Friedreichs Ataxia Market to Grow at a Substantial Growth Rate by 2034, Examines DelveInsight | Key Companies - Retrotope, PTC Therapeutics, Minoryx Therapeutics, Biogen, Lexeo Therapeutics, Larimar Therapeutics

The dynamics of Friedreichs ataxia market are anticipated to change as companies across the globe are thoroughly working toward the…

INVESTOR DEADLINE NEXT WEEK: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - BIIB

SAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or…

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit – BIIB

NEW YORK, July 15, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders…

BIIB Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. (BIIB) Investors of July 22, 2024 Deadline in Securities Fraud Class Action Lawsuit

RADNOR, Pa., July 14, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP…

BIIB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Case

SAN DIEGO, July 13, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or…

Biogens Diverse Drug Portfolio Faces Competitive Challenges In 2024

…

ANLEIHEN-Woche KW28 - 2024: Noratis, Verve, LEEF, Mutares, Katjes Greenfood, ESPG, MS Industrie, HPI, The Platform Group, Neon Equity, BIOGENA, hep, …

Kalenderwoche 28 am KMU-Anleihemarkt - die Noratis AG strebt eine dreijährige Laufzeit-Verlängerung der Anleihe 2020/25 (ISIN: DE000A3H2TV6) bis zum 31.…

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines – BIIB

NEW YORK, July 12, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been…

Aktie von Biogen unter Druck: Kurs fällt um 3,83 Prozent (209,1244 €)

Die Aktie von Biogen zählt heute zu den großen Verlierern am Aktienmarkt. Der Kurs des Wertpapiers sackt kräftig ab. Zu…

Kirby McInerney LLP Reminds Biogen, Inc. (BIIB) Investors of Class Action Filing and Encourages Investors to Contact the Firm

NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP notifies investors of…

dpa-AFX ProFeed